Declared Dividend • Aug 10
Dividend of US$0.20 announced Shareholders will receive a dividend of US$0.20. Ex-date: 14th August 2026 Payment date: 28th August 2026 Dividend yield will be 1.4%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (43% earnings payout ratio) and cash flows (42% cash payout ratio). The dividend has decreased over the past 46 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Aug 04
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to €80.50. The fair value is estimated to be €66.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 24% in 2 years. Earnings are forecast to grow by 31% in the next 2 years. Reported Earnings • Aug 04
Second quarter 2026 earnings released: EPS: US$0.41 (vs US$0.45 in 2Q 2025) Second quarter 2026 results: EPS: US$0.41 (down from US$0.45 in 2Q 2025). Revenue: US$20.5m (flat on 2Q 2025). Net income: US$5.22m (down 9.6% from 2Q 2025). Profit margin: 26% (down from 28% in 2Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Annonce • Jul 25
IRADIMED CORPORATION to Report Q2, 2026 Results on Jul 31, 2026 IRADIMED CORPORATION announced that they will report Q2, 2026 results Pre-Market on Jul 31, 2026 Buy Or Sell Opportunity • Jul 15
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 5.2% to €81.00. The fair value is estimated to be €67.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 22% in the next 2 years. Recent Insider Transactions • Jun 07
Independent Director recently sold €245k worth of stock On the 4th of June, Hilda Scharen-Guivel sold around 3k shares on-market at roughly €81.72 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.9m more than they bought in the last 12 months. Buy Or Sell Opportunity • May 12
Now 21% overvalued Over the last 90 days, the stock has fallen 17% to €71.50. The fair value is estimated to be €59.29, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 22% in the next 2 years. Declared Dividend • May 06
Dividend of US$0.20 announced Shareholders will receive a dividend of US$0.20. Ex-date: 15th May 2026 Payment date: 29th May 2026 Dividend yield will be 1.5%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (43% cash payout ratio). The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 34% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 05
First quarter 2026 earnings released: EPS: US$0.46 (vs US$0.37 in 1Q 2025) First quarter 2026 results: EPS: US$0.46 (up from US$0.37 in 1Q 2025). Revenue: US$22.0m (up 13% from 1Q 2025). Net income: US$5.82m (up 24% from 1Q 2025). Profit margin: 27% (up from 24% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Annonce • Apr 27
IRADIMED CORPORATION to Report Q1, 2026 Results on May 01, 2026 IRADIMED CORPORATION announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 01, 2026 Declared Dividend • Feb 16
Dividend of US$0.20 announced Shareholders will receive a dividend of US$0.20. Ex-date: 23rd February 2026 Payment date: 6th March 2026 Dividend yield will be 1.3%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (40% earnings payout ratio) and cash flows (73% cash payout ratio). The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 20% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 10
Full year 2025 earnings released: EPS: US$1.77 (vs US$1.52 in FY 2024) Full year 2025 results: EPS: US$1.77 (up from US$1.52 in FY 2024). Revenue: US$83.8m (up 14% from FY 2024). Net income: US$22.5m (up 17% from FY 2024). Profit margin: 27% (in line with FY 2024). Revenue is forecast to grow 8.8% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Feb 05
IRADIMED CORPORATION to Report Q4, 2025 Results on Feb 10, 2026 IRADIMED CORPORATION announced that they will report Q4, 2025 results Pre-Market on Feb 10, 2026 Recent Insider Transactions • Dec 11
Director recently sold €249k worth of stock On the 9th of December, James Hawkins sold around 3k shares on-market at roughly €83.01 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €779k. Insiders have been net sellers, collectively disposing of €1.3m more than they bought in the last 12 months. Annonce • Dec 09
Iradimed Corporation Approves Special Cash Dividend on Outstanding Common Stock, Payable on December 30, 2025 iRadimed Corporation announced that its Board of Directors approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. Recent Insider Transactions • Nov 23
Director recently sold €229k worth of stock On the 20th of November, James Hawkins sold around 3k shares on-market at roughly €76.47 per share. This transaction amounted to 8.9% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €779k. Insiders have been net sellers, collectively disposing of €1.2m more than they bought in the last 12 months. Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Hilda Scharen-Guivel was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Oct 28
IRADIMED CORPORATION to Report Q3, 2025 Results on Nov 03, 2025 IRADIMED CORPORATION announced that they will report Q3, 2025 results Pre-Market on Nov 03, 2025 Annonce • Sep 03
IRADIMED CORPORATION Announces Board Changes IRADIMED CORPORATION announced a Board of Directors transition. Anthony Vuoto has retired from his position as a director, effective August 27, 2025, after deciding it is time to step away following many years of dedicated service. Effective September 2, 2025, the Board has appointed Joe Kiani, Masimo founder and renowned medical technology innovator and entrepreneur, to fill the vacancy on the Board. Anthony Vuoto served as a director of Iradimed since 2016, providing valuable strategic guidance during a period of significant growth and innovation for the Company. Joining the Board is Joe Kiani, an industry pioneer with a distinguished track record in medical technology. Mr. Kiani is the founder of Masimo Corporation, where he served as Chairman and CEO from 1989 until 2024, growing the company into a global leader in non-invasive patient monitoring technologies, particularly pulse oximetry. Mr. Kiani is also the CEO of Willow Laboratories, a health and wellness innovator, and Like Minded Labs, a company focused on advanced video technologies, and he serves on the Board of Directors of CDX Medical Technologies, an early-stage respiratory care company. With over 500 patents or patent applications and a reputation for driving innovation, Mr. Kiani brings critical expertise to the Board. Mr. Kiani’s Board appointment is effective September 2, 2025, and he will serve on the Board’s audit committee and chairman of the compensation committee, helping to guide Iradimed’s growth in the medical device sector. Annonce • Jul 26
IRADIMED CORPORATION to Report Q2, 2025 Results on Aug 01, 2025 IRADIMED CORPORATION announced that they will report Q2, 2025 results Pre-Market on Aug 01, 2025 Annonce • May 29
IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System Iradimed Corporation announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium®? 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with first-generation device in 2005. The MRidium®? 3870 is poised to strengthen Iradimed's leadership for MRI-compatible infusion, addressing growing demands for safe and reliable fluid delivery in diagnostic imaging. TheMRidium®? 3870 features a non-magnetic ultrasonic pump motor, non-interfering RF emissions, and non-ferrous components, ensuring seamless performance in high-magnetic-field environments. Building on Iradimed's legacy of innovation, this next-generation system introduces an enhanced, intuitive graphical touchscreen user interface and advanced safety features. The 3870 can operate independently or be combined with additional 3870 pumps to operate as a four-channel IV infusion pump system for critical care patients. The 3870 also features a modern drug library solution that accommodates multiple patient care area drug listing, facilitating use in a wide variety of MRI applications and patient needs. These 3870 enhancements address the evolving needs of healthcare providers, driving patient safety and workflow efficiency during MRI scans. Iradimed plans a strategic rollout of the newly FDA-cleared MRidium®? 3870 infusion pump with initial unit deployment to select healthcare facilities in the fourth quarter of 2025. Material shipments growing towards full commercial distribution will ramp throughout 2026. Annonce • May 01
IRADIMED CORPORATION, Annual General Meeting, Jun 19, 2025 IRADIMED CORPORATION, Annual General Meeting, Jun 19, 2025. Location: 1025 willa springs drive, winter springs, florida 32708, United States Annonce • Apr 28
IRADIMED CORPORATION to Report Q1, 2025 Results on May 05, 2025 IRADIMED CORPORATION announced that they will report Q1, 2025 results Pre-Market on May 05, 2025 Annonce • Feb 14
IRADIMED CORPORATION Declares Regular Quarterly Cash Dividend for the First Quarter of 2025, Payable on March 5, 2025 IRADIMED CORPORATION announced increase in quarterly cash dividend from $0.15 to $0.17 per share. The Company’s board of directors declared a regular quarterly cash dividend of $0.17 per common share for the first quarter of 2025, of outstanding common stock, payable on March 5, 2025, to stockholders of record as of the close of business on February 24, 2025. Annonce • Feb 13
IRADIMED CORPORATION Provides Earnings Guidance for the First Quarter and Full Year 2025 IRADIMED CORPORATION provided earnings guidance for the first quarter and full year 2025. For the quarter, Company expected revenue of $19.2 million to $19.4 million, and GAAP diluted earnings per share of $0.35 to $0.39.
For the full year, Company expected to report revenue of $78.0 million to $82.0 million, GAAP diluted earnings per share of $1.55 to $1.65. Annonce • Jan 30
IRADIMED CORPORATION to Report Q4, 2024 Results on Feb 13, 2025 IRADIMED CORPORATION announced that they will report Q4, 2024 results Pre-Market on Feb 13, 2025 Annonce • Jan 11
IRADIMED CORPORATION Provides Earnings Guidance for the Fourth Quarter and Full Year 2024 IRADIMED CORPORATION provided earnings guidance for the fourth quarter and full year 2024. The company anticipates total revenue for the fourth quarter of 2024 to be in the range of approximately $19.2 million to $19.4 million, representing year-over-year growth of between 10% and 11% and sequential quarter-over-quarter growth of between 5% and 6%.
Full-year 2024 total revenue is expected to be in the range of approximately $73.1 million to $73.3 million, compared to $65.6 million in the prior year period, representing year-over-year growth of between 11% and 12%. Upcoming Dividend • Nov 08
Upcoming dividend of US$0.15 per share Eligible shareholders must have bought the stock before 15 November 2024. Payment date: 25 November 2024. Payout ratio is a comfortable 31% and the cash payout ratio is 80%. Trailing yield: 1.9%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (1.9%). Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to €51.50, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €101 per share. Reported Earnings • Nov 06
Third quarter 2024 earnings released: EPS: US$0.40 (vs US$0.40 in 3Q 2023) Third quarter 2024 results: EPS: US$0.40 (down from US$0.40 in 3Q 2023). Revenue: US$18.3m (up 11% from 3Q 2023). Net income: US$5.05m (flat on 3Q 2023). Profit margin: 28% (down from 31% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Annonce • Oct 25
IRADIMED CORPORATION to Report Q3, 2024 Results on Oct 31, 2024 IRADIMED CORPORATION announced that they will report Q3, 2024 results Pre-Market on Oct 31, 2024 Upcoming Dividend • Aug 13
Upcoming dividend of US$0.15 per share Eligible shareholders must have bought the stock before 20 August 2024. Payment date: 30 August 2024. Payout ratio is a comfortable 20% and the cash payout ratio is 76%. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (1.9%). Reported Earnings • Aug 05
Second quarter 2024 earnings released: EPS: US$0.39 (vs US$0.33 in 2Q 2023) Second quarter 2024 results: EPS: US$0.39 (up from US$0.33 in 2Q 2023). Revenue: US$17.9m (up 11% from 2Q 2023). Net income: US$4.90m (up 17% from 2Q 2023). Profit margin: 27% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Annonce • Jul 25
IRADIMED CORPORATION to Report Q2, 2024 Results on Aug 01, 2024 IRADIMED CORPORATION announced that they will report Q2, 2024 results Pre-Market on Aug 01, 2024 Recent Insider Transactions • Jun 06
Independent Director recently sold €78k worth of stock On the 3rd of June, Monty Allen sold around 2k shares on-market at roughly €39.84 per share. This transaction amounted to 9.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €191k more than they bought in the last 12 months. Annonce • May 01
IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024 IRADIMED CORPORATION, Annual General Meeting, Jun 20, 2024, at 10:00 Eastern Daylight. Location: 1025 Willa Springs Drive, Winter Springs Florida United States Agenda: To elect the directors until the 2025 annual meeting of stockholders and until his successor is duly elected and shall qualify, or until his earlier death, resignation, disqualification or removal; to ratify the appointment of rsm us llp as the independent registered public accounting firm of the company for the year ending December 31, 2024; and to approve, on a non-binding advisory basis, the fiscal 2023 compensation of the company’s named executive officers. Annonce • Apr 28
IRADIMED CORPORATION to Report Q1, 2024 Results on May 02, 2024 IRADIMED CORPORATION announced that they will report Q1, 2024 results Pre-Market on May 02, 2024 Reported Earnings • Mar 06
Full year 2023 earnings released: EPS: US$1.36 (vs US$1.02 in FY 2022) Full year 2023 results: EPS: US$1.36 (up from US$1.02 in FY 2022). Revenue: US$65.6m (up 23% from FY 2022). Net income: US$17.2m (up 34% from FY 2022). Profit margin: 26% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Annonce • Feb 08
IRadimed Corporation Provides Revenue Guidance for the First Quarter and Full Year of 2024 IRadimed Corporation provided revenue guidance for the first quarter and full year of 2024. For the period, the company expects to report revenue of $17.0 million to $17.3 million, GAAP diluted earnings per share of $0.29 to $0.31.For the year, the company expects to report revenue of $72.0 million to $74.0 million, GAAP diluted earnings per share of $1.37 to $1.47, and non-GAAP diluted earnings per share of $1.52 to $1.62. Annonce • Feb 02
IRadimed Corporation to Report Q4, 2023 Results on Feb 08, 2024 IRadimed Corporation announced that they will report Q4, 2023 results Pre-Market on Feb 08, 2024 Annonce • Nov 04
Iradimed Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 IRadimed Corporation provided earnings guidance for the fourth quarter and full year 2023. For the fourth quarter of 2023, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38.For the full-year 2023 financial guidance, the Company now expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37. Annonce • Oct 27
IRadimed Corporation to Report Q3, 2023 Results on Nov 03, 2023 IRadimed Corporation announced that they will report Q3, 2023 results Pre-Market on Nov 03, 2023 Annonce • Aug 04
IRadimed Corporation Provides Earnings Guidance for the Third Quarter and for the Full Year of 2023 IRadimed Corporation provided earnings guidance for the third quarter and for the full year of 2023. For the quarter, the company expects to report revenue of $16.1 million to $16.3 million, GAAP diluted earnings per share of $0.33 to $0.35.For the year, the company now expects to report revenue of $64.5 million to $65.5 million, GAAP diluted earnings per share of $1.25 to $1.28. Annonce • Jul 29
IRadimed Corporation to Report Q2, 2023 Results on Aug 03, 2023 IRadimed Corporation announced that they will report Q2, 2023 results Pre-Market on Aug 03, 2023 Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to €33.00, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total returns to shareholders of 46% over the past three years. Reported Earnings • Feb 07
Full year 2022 earnings released: EPS: US$1.02 (vs US$0.76 in FY 2021) Full year 2022 results: EPS: US$1.02 (up from US$0.76 in FY 2021). Revenue: US$53.3m (up 28% from FY 2021). Net income: US$12.8m (up 38% from FY 2021). Profit margin: 24% (up from 22% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 3.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annonce • Feb 03
Iradimed Corporation Approves Special Cash Dividend, Payable on February 21, 2023 The Board of Directors of IRadimed Corporation approved a special cash dividend of $1.05 per share. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13, 2023. Annonce • Jan 27
IRadimed Corporation to Report Q4, 2022 Results on Feb 02, 2023 IRadimed Corporation announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 02, 2023 Annonce • Jan 20
IRadimed Corporation Provides Earnings Guidance for the First Quarter of 2023 and Full Year 2023 IRadimed Corporation provided earnings guidance For the first quarter of 2023 and full year 2023. For the period, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34. Annonce • Nov 04
Iradimed Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022 IRadimed Corporation provided revenue guidance for the fourth quarter and full year 2022. For quarter the Company's prior revenue guidance remains unchanged as it expects to report revenue of $14.1 million to $14.8 million. The Company expects to report GAAP diluted earnings per share of $0.23 to $0.28 per share . For full-year the company expects revenue of $52.5 million to $53.2 million. Annonce • Oct 28
IRadimed Corporation to Report Q3, 2022 Results on Nov 03, 2022 IRadimed Corporation announced that they will report Q3, 2022 results on Nov 03, 2022 Annonce • Oct 12
IRadimed Corporation Provides Revenue Guidance for the Third Quarter Ended September 30, 2022 IRadimed Corporation provided revenue guidance for the third quarter ended September 30, 2022. Third-quarter revenue is expected to be approximately $13.4 million, up 23% from the prior year and above the Company’s third-quarter guidance of $13.1 million to $13.3 million. Annonce • Oct 07
IRadimed Corporation Announces Board Changes The Board of Directors of iRadimed Corporation increased the size of the Board to a total of 5 Directors and elected Ms. Hilda Scharen-Guivel as a Director, both effective October 4, 2022. The Board has not elected Ms. Scharen-Guivel to any Board Committee at this time. Ms. Scharen-Guivel does not have any material relationships with the Company, and there are no transactions between her and the Company that would be required to be reported under Item 404(a) of Regulation S-K. There is also no arrangement or understanding between Ms. Scharen-Guivel and the Company pursuant to which she was selected as a Director. Ms. Scharen-Guivel will receive compensation generally consistent with that received by non-employee Directors, as described in the Company’s most recent Proxy Statement for the 2022 Annual Meeting of Stockholders. Recent Insider Transactions • Aug 06
Independent Director recently sold €113k worth of stock On the 4th of August, Monty Allen sold around 3k shares on-market at roughly €36.86 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.1m more than they bought in the last 12 months. Board Change • Aug 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Jim Hawkins was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 29
Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.12 in 2Q 2021) Second quarter 2022 results: EPS: US$0.26 (up from US$0.12 in 2Q 2021). Revenue: US$12.7m (up 30% from 2Q 2021). Net income: US$3.24m (up 121% from 2Q 2021). Profit margin: 26% (up from 15% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 7.0% growth forecast for the industry in Germany. Annonce • Jul 23
IRadimed Corporation to Report Q2, 2022 Results on Jul 29, 2022 IRadimed Corporation announced that they will report Q2, 2022 results Pre-Market on Jul 29, 2022 Board Change • Jul 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Jim Hawkins was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annonce • May 27
IRadimed Corporation Names John F. Glenn as Chief Financial Officer, Effective on or before June 20, 2022 IRADIMED CORPORATION announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022. Mr. Glenn will assume responsibility for all areas of accounting and finance, including business planning and modeling, organizational resource planning, investor and analyst relations, and required reporting and related filings with the SEC. Mr. Glenn, 60, is a Financial Executive with over 30 years’ experience directing corporate finance activities of public and private companies with an established record in significantly growing enterprise value. Mr. Glenn comes to IRADIMED from Esko Bionics Holdings Inc., a developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Prior to serving as Chief Financial Officer at Esko Bionics, Mr. Glenn served as Chief Financial Officer for Sonendo Inc. His prior experience also includes serving as Chief Financial Officer, at several other companies, including Armetheon Corporation; Solta Medical, where he assisted in the company’s strategic acquisition by Valeant Pharmaceutical; Cholestech, which was acquired by Alere Medical; and Invivo Corporation, which was sold to Intermagnetics General Corporation. Mr. Glenn received his MBA in Finance from Santa Clara University and his B.S. in Business Administration from the University of Nevada. Annonce • Apr 06
IRadimed Corporation to Report Q1, 2022 Results on Apr 29, 2022 IRadimed Corporation announced that they will report Q1, 2022 results Pre-Market on Apr 29, 2022 Reported Earnings • Mar 05
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$0.76 (up from US$0.11 in FY 2020). Revenue: US$41.8m (up 32% from FY 2020). Net income: US$9.33m (up US$7.96m from FY 2020). Profit margin: 22% (up from 4.3% in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 24%, compared to a 11% growth forecast for the industry in Germany. Annonce • Feb 08
IRadimed Corporation Announces Special Share Cash Dividend, Payable on February 24, 2022 IRADIMED CORPORATION announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company’s outstanding common stock. This special cash dividend is payable on February 24, 2022 to shareholders of record at the close of business on February 17, 2022. Annonce • Feb 05
iRadimed Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2022 iRadimed Corporation provided earnings guidance for the first quarter and full year of 2022. For the quarter, the company expects to report revenue in the range of $12.1 million to $12.3 million, GAAP diluted earnings per share in the range of $0.16 to $0.18.For the full year 2022, the company expects to report revenue in the range of $51.4 million to $52.2 million, GAAP diluted earnings per share in the range of $0.82 to $0.90. Recent Insider Transactions • Dec 15
Independent Director recently sold €785k worth of stock On the 7th of December, James Hawkins sold around 19k shares on-market at roughly €41.88 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €903k more than they bought in the last 12 months. Reported Earnings • Jul 31
Second quarter 2021 earnings released: EPS US$0.12 (vs US$0.17 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.81m (up 44% from 2Q 2020). Net income: US$1.47m (up US$3.58m from 2Q 2020). Profit margin: 15% (up from net loss in 2Q 2020). Reported Earnings • May 04
First quarter 2021 earnings released: EPS US$0.11 (vs US$0.15 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: US$9.22m (up 6.3% from 1Q 2020). Net income: US$1.39m (down 22% from 1Q 2020). Profit margin: 15% (down from 20% in 1Q 2020). Annonce • May 01
IRadimed Corporation Provides Financial Guidance for Fiscal Year 2021 IRadimed Corporation provided financial guidance for fiscal year 2021. Significant uncertainty remains regarding the impact of COVID-19 on the company’s financial results. Accordingly, the company believes it is prudent to refrain from providing financial guidance at this time. The company continues to monitor the circumstances around the pandemic and will provide financial guidance once there is more certainty around the pandemic’s impact on its business. Reported Earnings • Feb 06
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$31.7m (down 18% from FY 2019). Net income: US$1.37m (down 86% from FY 2019). Profit margin: 4.3% (down from 25% in FY 2019). Analyst Estimate Surprise Post Earnings • Feb 06
Revenue beats expectations Revenue exceeded analyst estimates by 1.7%. Over the next year, revenue is forecast to grow 10%, compared to a 14% growth forecast for the Medical Equipment industry in Germany. 
